Hanmi Pharmaceutical
VC Fund
Seoul, South Korea
Hanmi Pharmaceutical is a VC fund in Seoul focused on Biotechnology and Biopharma. Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years.Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy fromfirst generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies.Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories.As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries Hanmi Pharmaceutical invests in
Stages Hanmi Pharmaceutical invests in
Countries Hanmi Pharmaceutical invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 5 (45%)
- Biopharma 3 (27%)
- Health Care 3 (27%)
- Pharmaceutical 3 (27%)
- Clinical Trials 2 (18%)
Stage
- Seed 2 (18%)
- Corporate Round 2 (18%)
- Post-IPO Equity 2 (18%)
- Series C 1 (9%)
- Post-IPO Debt 1 (9%)
Country
- United States 4 (36%)
- South Korea 2 (18%)
- Canada 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chong-Yoon Lim
President & CEO
|
President & CEO | Total investments: 0 | Find email | |
|
Gwan-Sun Lee
President & CEO
|
President & CEO | Total investments: 0 | Find email | |
|
Sung-ki Lim
Chairman & CEO / Founder
|
Chairman & CEO / Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical toclinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization. | $11.9M / Post-IPO Debt / Sep 22, 2025 | ||
| Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical toclinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization. | $7.1M / Post-IPO Debt / Jun 20, 2025 | ||
| MEDiC is focusing on cancer drug targets in 3D tumor models using its proprietary CRISPR functional genomics platform. The biotech company is based in the San Francisco Bay Area. | $5M / Corporate Round / Oct 14, 2024 | ||
| Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical toclinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization. | $7.4M / Post-IPO Debt / Aug 30, 2024 | ||
| Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical toclinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization. | $4M / Post-IPO Equity / Jan 26, 2024 | ||
| Aptose Biosciences is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical toclinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization. | Post-IPO Equity / Sep 06, 2023 | ||
|
Digital Pharm
|
Digital Pharm is a pharmaceutical company that specializes in electroceuticals and DTx. | Corporate Round / Apr 01, 2022 | |
| Spectrum Pharmaceuticals is a commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a focus in oncology and hematology. | $20M / Post-IPO Equity / Jan 04, 2022 | ||
| EvidNet is a heathcare IT company that provides Real World Evidence (RWE) solutions based on hospital data, empowers R&D and business decision-making in the life sciences and healthcare industries. We works with over 50 university hospitals and tertiary/general hospitals in Korea to build Real World Data (RWD) using the OMOP-CDM standard,our FeederNet® data platform enables multi-institutional research and AI Federated M/L without compromising on privacy and security. Our solutions and AI technologies provide a wide range of insights for customers from R&D to commercialization. | Seed / Nov 12, 2018 | ||
| Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating newbrain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000. | $3.7M / Seed / Oct 01, 2017 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Hanmi Pharmaceutical invest in?
Hanmi Pharmaceutical invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Seed and Corporate Round stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Hanmi Pharmaceutical?
Public channels for Hanmi Pharmaceutical include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hanmi Pharmaceutical?
The team at Hanmi Pharmaceutical includes Chong-Yoon Lim (President & CEO), Gwan-Sun Lee (President & CEO) and Sung-ki Lim (Chairman & CEO / Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
